{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.1","upperLimit":"17.8","value":"3.4"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"11.2","value":"0"},{"groupId":"OG002","lowerLimit":"2.3","upperLimit":"28.2","value":"10.7"},{"groupId":"OG003","lowerLimit":"1.7","upperLimit":"14.6","value":"6.0"},{"groupId":"OG004","lowerLimit":"0.8","upperLimit":"22.1","value":"6.7"},{"groupId":"OG005","lowerLimit":"5.6","upperLimit":"34.7","value":"16.7"},{"groupId":"OG006","lowerLimit":"0.0","upperLimit":"11.6","value":"0"},{"groupId":"OG007","lowerLimit":"0.2","upperLimit":"41.3","value":"9.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"31"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"67"},{"groupId":"OG004","value":"30"},{"groupId":"OG005","value":"30"},{"groupId":"OG006","value":"30"},{"groupId":"OG007","value":"11"}],"units":"Participants"}],"description":"Objective response rate is defined as the percentage of participants with confirmed responses of either complete response (CR) or partial response (PR). Response was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 by independent central review.\n\nComplete Response: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 mm.\n\nPartial Response: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with NSCLC with no prior exposure to any PD-1 pathway targeting drug (PD-1 naïve) received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG000","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W: NSCLC (PD-1 Naïve)"},{"description":"Participants with NSCLC with de novo or acquired resistance to an anti-PD-1 targeting drug (PD-1 resistant) received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG001","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W: NSCLC (PD-1 Resistant)"},{"description":"Participants with SCCHN received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG002","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W: SCCHN"},{"description":"Participants with pancreatic cancer received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG003","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W: Pancreatic Cancer"},{"description":"Participants with advanced ovarian cancer received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG004","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W: Ovarian Cancer"},{"description":"Participants with RCC received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG005","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W: RCC"},{"description":"Participants with malignant glioma received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG006","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W: GBM"},{"description":"Participants with melanoma received 4 mg/kg cabiralizumab IV and 3 mg/kg nivolumab IV Q2W until disease progression, unacceptable toxicity, or other reason for treatment discontinuation.","id":"OG007","title":"Cabiralizumab 4 mg/kg + Nivolumab 3 mg/kg Q2W: Melanoma"}],"paramType":"NUMBER","populationDescription":"Response-evaluable population based on central review assessment included all participants who had at least 1 post-baseline tumor assessment, or clinical progression, or death.\n\nEfficacy endpoints were specified to be analyzed by disease type for phase 1b participants only.","reportingStatus":"POSTED","timeFrame":"Tumor response was assessed every 8 weeks from first dose for the first 12 months and then every 12 weeks thereafter until end of treatment; maximum duration of treatment was 156 weeks.","title":"Efficacy: Objective Response Rate - Central Review Assessment (Phase 1b)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}